These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 31215111

  • 1. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability.
    Siguret V, Abdoul J, Delavenne X, Curis E, Carlo A, Blanchard A, Salem JE, Gaussem P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA, Lecompte T, Gouin-Thibault I.
    J Thromb Haemost; 2019 Oct; 17(10):1670-1682. PubMed ID: 31215111
    [Abstract] [Full Text] [Related]

  • 2. Study of thrombin generation with St Genesia to evaluate xaban pharmacodynamics: Analytical performances over 18 months.
    Foulon-Pinto G, Jourdi G, Perrin J, Abdoul J, Paris G, Gouin-Thibault I, Curis E, Lecompte T, Siguret V.
    Int J Lab Hematol; 2021 Aug; 43(4):821-830. PubMed ID: 33369212
    [Abstract] [Full Text] [Related]

  • 3. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, Becka M, Hemmrich M.
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [Abstract] [Full Text] [Related]

  • 4. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
    Perzborn E, Heitmeier S, Buetehorn U, Laux V.
    J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD, Alberio L, Angelillo-Scherrer A, Asmis LM, Fontana P, Korte W, Mendez A, Schmid P, Stricker H, Tsakiris DA, Wuillemin WA, Nagler M.
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [Abstract] [Full Text] [Related]

  • 7. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
    Levy JH, Moore KT, Neal MD, Schneider D, Marcsisin VS, Ariyawansa J, Weitz JI.
    J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose.
    Santos AFD, Francisco QAS, Nunes JB, Colombo FA, Boralli VB.
    Braz J Med Biol Res; 2024 Jan; 57():e13257. PubMed ID: 38958362
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients.
    Kaserer A, Schedler A, Jetter A, Seifert B, Spahn DR, Stein P, Studt JD.
    Thromb Haemost; 2018 May; 118(5):808-817. PubMed ID: 29614520
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.